

Exhibit B

Exhibit B

Summary of Generic Entry

		Generic Equivalents									
		1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
Blenoxane	<i>Company Launch Date</i>	Pharmacia/ Pfizer Jul-96	Mayne Apr-00	Sicor Aug-00	Bedford Mar-03						
Cytoxan	<i>Company Launch Date</i>	Neosar Pharmacia Nov-83	Wyeth Apr-88	Baxter Jun-04							
Cytoxan Tablet	<i>Company Launch Date</i>	Roxane Apr-00									
Etopophos*	<i>Company Launch Date</i>										
Paraplatin	<i>Company Launch Date</i>	Sicor Jul-04	Bedford Oct-04	BMS Oct-04	American Pharma Oct-04	Mayne Oct-04	Baxter Nov-04	Pliva Mar-05	Cura Pharma Aug-05		
Rubex **	<i>Company Launch Date</i>	Bedford Apr-89	Rubex BMS** May-89	Unknown Oct-89	Astrazeneca Jul-90	Pharmacia Apr-91	Sicor Oct-95	American Pharma Feb-96	Private Label Aug-99	Baxter Jan-01	
Taxol	<i>Company Launch Date</i>	Onxol Ivax Nov-00	Mylan Aug-01	Bedford Sep-01	Mayne May-02						
VePesid*	<i>Company Launch Date</i>	Sicor Feb-94	Toposar Pharmacia/ Pfizer May-95	Bedford Nov-95	Hospira Mar-96	Astrazeneca Apr-96	Supergen Jul-96	Watson Dec-96	Marsam Pharma Aug-98	American Pharma Apr-00	Baxter Dec-00
VePesid Capsule	<i>Company Launch Date</i>	Mylan Nov-01	Unit Dose Lab Nov-01								

Sources: IMS sales data

Notes:

* Etopophos, which did not face generic competition, and injectable etoposide are reimbursed under the same J-codes (J9181 and J9182).

** Rubex is a branded generic version of Pharmacia's Adriamycin, which was originally approved in 1974. Rubex was marketed by Immunex Corporation in 1992 and 1993 and by BMS thereafter.

Defendants' Exhibit

2637

01-12257 - PBS